4Hung SI, Chung WH, Liou LB, et al. HLA-B*5801allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proe Nat Acad Sei USA, 2005, 102 (11) :4134-4139.
4Stella M, Cassano P, Bollero D, et al. Toxic epidermal necrolysis treated with intravenous high -dose immunoglobulins: our experience[J]. Dermatology, 2001, 203 (1): 45-49.
5Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin[J]. Science, 1998, 282 (5388): 490-493.
6Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature, 2004, 428 ( 6982 ):486.
7Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J, 2006, 6 ( 4 ) : 265-268.
8French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int, 2006, 55 (1): 9-16.
9Hung SI, Chung WH, Liou LB, et al. HLA-B^*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A, 2005, 102 ( 11 ) : 4134-4139.
10Paquet P, Pierard GE, Quatresooz P. Novel treatments for drug-induced toxic epidermal necrolysis ( Lyelrs syndrome ). Int Arch Allergy Immunol, 2005, 136( 3 ) : 205-216.
